We describe a 74-year-old man with rheumatoid arthritis (RA) who developed syndrome of inappropriate secretion of antidiuretic hormone (SIADH) 1.5 months after commencement of mizoribin prescription when his arthritis was improved. He noticed nausea and headache and serum Na fell as low as 118 mEq/l. Normal urinary Na excretion without hypotension or hemoconcentration negated the possibility of dehydration resulting from urinary Na loss. Serum antidiuretic hormone (ADH) remained elevated at 0.59 pg/ml in spite of a significant reduction in serum osmolality to 254 mosm/kg. He had no organic disease likely to cause SIADH. Despite infusion of hypertonic saline, his serum Na was not restored to normal. Shortly after mizoribin withdrawal, his serum Na increased significantly from 128 to 139 mEq/l and plasma osmolality from 265 to 287 mosm/kg. ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that bredinin might adversely induce SIADH. Additional predisposing factors were the patient’s age and difficulty in urination due to benign prostatic hypertrophy. In summary, we report herein the first case of SIADH believed to be an adverse effect of mizoribin, which may therefore needed to be added to the list of drugs which can induce SIADH.

Keywords:
Syndrome of inappropriate secretion of antidiuretic hormone, Hyponatremia, Mizoribin, Drug, Disease-modifying antirheumatic drugs
1.
Kashyap AS, Kashyap S: Drug induced syndrome of inappropriate antidiuretic hormone secretion. Postgrad Med J 2000;76:319.
2.
Petersson I, Nilsson G, Hansson BG, Hedner T: Water intoxication associated with non-steroidal anti-inflammatory drug therapy. Acta Med Scand 1987;221:221–223.
3.
Bressler RB, Huston DP: Water intoxication following moderate-dose intravenous cyclophosphamide. Arch Intern Med 1985;145:548–549.
4.
Iwata H, Iwaki H, Masukawa T, Kasamatsu S, Okamoto H: Anti-arthritic activity of bredinin, an immunosuppressive agent. Experientia 1977;33:502–503.
5.
Zerbe RL, Miller JZ, Robertson GL: The reproducibility and heritability of individual differences in osmoregulatory function in normal human subjects. J Lab Clin Med 1991;117:51–59.
6.
Okuno S, Inaba M, Nishizawa Y, Miki T, Inoue Y, Morii H: A case of hyponatremia in panhypopituitarism caused by the primary empty sella syndrome. Endocrinol Jpn 1987;34:299–307.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.